University of Rochester Medical Center to begin HIV study Rochester Democrat and Chronicle, NY - In December 2004, the URMC, along with 26 other sites in nine countries, began testing what was a promising Merck vaccine in 3000 participants considered at ...ROCM
London hospital to test new HIV vaccine candidate Aidsmap, UK - Nov 28, 2008 The St Stephen?s AIDS Trust of the Chelsea and Westminster hospital in London has teamed up with the International AIDS Vaccine Initiative (IAVI), ...
Phase I Clinical Trial to Test Combination of Two HIV Vaccine... innovations report, Germany - Nov 28, 2008 The International AIDS Vaccine Initiative (IAVI) and the St. Stephen?s AIDS Trust at the Chelsea and Westminster Hospital have initiated a Phase I clinical ...
Search For AIDS Vaccine Ramps Up Chemical & Engineering News - Nov 16, 2008 But Berkley is confident that drug company interest will return if a promising vaccine candidate emerges from a biotech company, IAVI's new labs, ...
PLHIV still on a narrow edge? As victims still stigmatized Modern Ghana, Ghana - Nov 27, 2008 According to AIDS Vaccine Initiative International (IAVI), scientists will work together with partners to compare, prioritise and advance promising AIDS...
Source: Google News
Recent News and Articles on the Keywords: seen + vaccine + future Related to the article below (Last Update: 8/7/2008)
Papers pondering Brown's future BBC News, UK - The message is to be sent to parents of the three million children who have not had the MMR vaccine. Many of the tabloids have returned the disappearance of ...
Letter To Donald Rumsfeld Hartford Courant, United States - As a result, we are troubled by several reports and actions that raise questions about whether continuing to administer the current anthrax vaccine is in ...
Pneumococcal vaccination: current and future issues - A Ortqvist - European Respiratory Journal, 2001 - Eur Respiratory Soc ... types 6A, 9N, 18B, 19A, 23A) was 51% (95% CI, 27?67%), while the reverse was seen
for all ...Future prospects of new pneumococcal vaccine formulations The ...
Science, medicine, and the future: The search for an HIV vaccine - MW Makgoba - BMJ, 2002 - pubmedcentral.nih.gov ... The search for an HIV vaccine was seen as the logical solution to the ... If we fail
to provide the world with an effective HIV vaccine, future generations will ...
Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future - ML Michel, S Pol, C Brechot, P Tiollais - Vaccine, 2001 - Elsevier ... should be considered in the future and combined ... administration of this single epitope vaccine initiate CTL ... with a magnitude well below that seen in patients ...
Vaccine technologies: view to the future - NR Rabinovich, P McInnes, DL Klein, BF Hall - Science, 1994 - sciencemag.org ... The CVI envisions the ideal vaccines of the future to be safe, heat-stable ... in life
(1). These objectives are now more firmly integrated in vaccine research and ...
BCG vaccination against tuberculosis: past disappointments and future hopes - PW Roche, JA Triccas, N Winter - Trends in Microbiology, 1995 - Elsevier ... some of the factors that are respon- sible for the variable protection seen and
how some of these factors may be overcome in futurevaccine strategies against ...
Vaccine adjuvants: Current state and future trends. - N PETROVSKY, JC AGUILAR - Immunology & Cell Biology, 2004 - pt.wkhealth.com ... This could be seen as analogous to throwing out the baby with the bath water. ... Future prospects for vaccine adjuvants. CRC Crit. Rev. Immunol. ...
The future of respiratory syncytial virus vaccine development. - FP POLACK, RA KARRON - The Pediatric Infectious Disease Journal, 2004 - pidj.org ... pp S65-S73. The future of respiratory syncytial virus vaccine development.
POLACK, FERNANDO P. MD; KARRON, RUTH A. MD. From the Center ...
Source: Google Scholar
Future seen promising for AIDS vaccine
There is no vaccine against AIDS and none of the dozens of vaccines being tested is likely to completely protect people from the deadly virus, but the future looks bright for AIDS vaccine development, researchers said on Tuesday.
Scientists will learn from the vaccines now being tested, and the developing world, hardest hit by HIV, is starting to produce its own vaccine effort, said Dr. Seth Berkley, head of the nonprofit International AIDS Vaccine Initiative.
"An AIDS vaccine is the only tool that can end the pandemic," Berkley told a news conference to launch a biennial report on vaccines at the 16th International AIDS Conference in Toronto.
All evidence suggests that a vaccine is possible. There is progress being made. It's slow but it's steady," he added.
"To me, we are about to enter a renaissance in AIDS vaccine research."
Yet Berkley said only two AIDS vaccine candidates are in advanced human trials -- one made by Merck and Co. and another by Sanofi-Aventis SA.
"The next major milestone for the field is likely to be the Merck result, which is a test for cellular immunity," Berkley said.
Berkley and others do not expect the Merck vaccine will protect against disease in the way, for instance, a measles vaccine does.
The AIDS virus infects more than 39 million people globally, more than 60 percent of them in sub-Saharan Africa. It kills more than 4 million people every year and has killed 25 million people since it was identified in the 1980s.
It is difficult to vaccinate against because the virus infects the very immune system cells that are usually stimulated by a vaccine.
"This is probably the toughest adversary that has ever been out there for vaccine development," Berkley said.
Most vaccine stimulate antibodies, immune system proteins that mark enemy invaders for destruction. Vaccine researchers believe that a good AIDS vaccine will have to stimulate both antibodies and so-called cellular immunity, which is the job of T-cells, dendritic cells and other immune cells.
Berkley hopes results of how well the Merck vaccine works will be available in 2008. If it reduces infection rates by even a little, scientists can study the volunteers and see just what successful aspects could be used as clues for further research.
If it does not work at all, whole new approaches will have to be pursued.
Even a partially effective vaccine could be useful, said Stephen Lewis, the United Nations delegate to Africa for AIDS.
"I think it's fair to say ... even a modestly effective vaccine could cut the number of new infections by one-third over a decade, saving tens of millions of lives," Lewis told the news conference.
One obstacle to testing vaccines is a lack of volunteers and facilities to do the clinical trials, the tests in people that show whether a vaccine or drugs works.
"We have dramatically improved the ability to do clinical trials," Berkley said. Ten years ago such trials were only done in industrialized countries, but now they are being run in two dozen developing countries, he said.
And funding for trials has doubled over the past five years, he said.
(For more stories related to the Toronto international AIDS Conference, please go to http://today.reuters.com/news/globalcoverage.aspx?type=aids&src= GLOBALCOVERAGE_wire)
